Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis

NCT06383468 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT06383468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06383468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Akeso
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2024
Completion date
January 30, 2026
Enrollment
420 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis